Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Other Long-Term Assets
Tibet Rhodiola Pharmaceutical Holding Co
Other Long-Term Assets Peer Comparison
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Other Long-Term Assets
¥118.8m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
25%
|
CAGR 10-Years
33%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Other Long-Term Assets
¥5.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Other Long-Term Assets
¥2.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
16%
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Other Long-Term Assets
¥606.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
31%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Other Long-Term Assets
¥830.1m
|
CAGR 3-Years
55%
|
CAGR 5-Years
34%
|
CAGR 10-Years
18%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Other Long-Term Assets
¥1.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
22%
|
CAGR 10-Years
38%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Other Long-Term Assets?
Other Long-Term Assets
118.8m
CNY
Based on the financial report for Mar 31, 2024, Tibet Rhodiola Pharmaceutical Holding Co's Other Long-Term Assets amounts to 118.8m CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
33%
Over the last year, the Other Long-Term Assets growth was 46%. The average annual Other Long-Term Assets growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been -25% over the past three years , 25% over the past five years , and 33% over the past ten years .